bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
PUBLISHED ON December 6, 2021
December 6, 2021 (San Antonio, TX) bioAffinity Vice President of Research David Elzi, Ph.D., will discuss how bioAffinity successfully uses RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), held virtually Dec. 6-11, 2021.
read more